H. Lundbeck and Otsuka Pharmaceutical have entered a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist in Phase III development for the treatment of Alzheimer’s disease. Lundbeck will grant Otsuka co-development and co-commercialization rights to Lu AE58054 in the U.S., Canada, East Asia, and major European and Nordic countries.   Lundbeck will receive an initial payment of $150 million and both companies will share the sales, development, and commercia...